Patrick Daly

DocwireNews

According to Stephanie Lee, MD, MPH, the association between organ responses and patient-reported outcomes (PROs) changes during belumosudil therapy for chronic graft-versus-host disease (cGVHD) is unclear. Dr. Lee and colleagues examined clinical trial data and concluded that &ldquo;there is a very strong but not universal correlation between organ clinical response measures and clinically meaningful changes in PROs recommended by the National Institutes of Health consensus conference in patients treated with belumosudil.&rdquo; Their findings were presented at the Transplantation &amp; Cellular Therapy 2022 Tandem Meetings.Specifically, Dr. Lee reported that &ldquo;there is excellent correlation of the skin, mouth, eye, upper GI, lung (clinical but not [forced expiratory volume in one second, or] FEV1%), and overall measures.&rdquo; Conversely, the study found that joint, esophagus, lower gastrointestinal (GI), and FEV1% measures exhibited a poor correlation with clinical organ responses, which the authors theorized could mean these PROs &ldquo;may be measuring different manifestations, or the clinician or PRO measures may be inadequately sensitive to change in cGVHD.&rdquo;The analysis included PROs from all dosage groups in both belumosudil trials (NCT02841995 and NCT03640481), and the generalized estimating equation (GEE) was used to account for missing or repeated data. The final assessment included 170 patients, 70% of which had severe cGVHD. The study did not analyze liver and genital tract measures due to a lack of PROs specific to those sites.Over a median follow-up of 15 months (range: 0.6&ndash;44 months), organ responses&mdash;complete or partial&mdash;were observed in 48/135 patients (35%) for skin, 84/124 (67.7%) for joint, 56/99 (57%) for mouth, 52/128 (41%) for eye, 19/26 (73%) for upper GI, 13/15 (87%) for lower GI, and 14/61 (23%) for lung, with an overall total of 130/170 (77%). These authors identified the described PROs as having meaningful associations to organ response.&ldquo;Overall, these data support use of PROs for response assessment in cGVHD clinical trials and patient care to help capture the patient&rsquo;s perspective on cGVHD disease activity,&rdquo; the researchers proposed in closing.

Jordana Jampel

Systematic Review of Suicide, Self-Harm Potentiality in GLP-1 RA Trials

Metabolic Disorders

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Latest News

Patient-Reported Outcomes and Organ Responses in Belumosudil Studies

Oncology

According to Stephanie Lee, MD, MPH, the association between organ responses and patient-reported outcomes (PROs) changes during belumosudil therapy for chronic ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe